Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin GB0009895292
Ticker AZN
Company ASTRAZENECA
Currency $
Price
Aware Investor Index (AII) 77.8115
Recommendation STRONG BUY
P/E 9.73
ROE 29.38 %
Capitalization 47,588,520,000 $
Dividend Yield 7.45 %
P/S 2.36
AII Position 31
P/E Position 48
ROE Position 91
Capitalization Position 192
Dividend Yield Position 18
Sales 20,152,000,000 $
10-Year Average Earnings 4,888,800,000 $
Shares Outstanding 1,267,000,000
Equity 16,642,000,000 $
Dividend per Share 2.8 $
Industry Pharmaceutical
Country Great Britain
ASTRAZENECA Investor Relations Web Site http://www.astrazeneca.com/Investors







Sales:

YEAR MONTH AMOUNT
2017 12 20,152,000,000.00 $
2016 12 21,319,000,000.00 $
2015 12 23,641,000,000.00 $
2014 12 26,095,000,000.00 $
2013 12 25,711,000,000.00 $
2012 12 27,973,000,000.00 $
2011 12 33,591,000,000.00 $
2010 12 33,269,000,000.00 $
2009 12 32,804,000,000.00 $
2008 12 31,601,000,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 2,868,000,000.00 $
2016 12 3,406,000,000.00 $
2015 12 2,826,000,000.00 $
2014 12 -271,000,000.00 $
2013 12 2,458,000,000.00 $
2012 12 6,405,000,000.00 $
2011 12 9,470,000,000.00 $
2010 12 8,106,000,000.00 $
2009 12 7,490,000,000.00 $
2008 12 6,130,000,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 16,642,000,000.00 $
2016 12 16,669,000,000.00 $
2015 12 18,509,000,000.00 $
2014 12 19,646,000,000.00 $
2013 12 23,253,000,000.00 $
2012 12 23,952,000,000.00 $
2011 12 23,472,000,000.00 $
2010 12 23,410,000,000.00 $
2009 12 20,821,000,000.00 $
2008 12 16,060,000,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 1,267,000,000
2016 12 1,266,000,000
2015 12 1,265,000,000
2014 12 1,264,000,000
2013 12 1,254,000,000
2012 12 1,261,000,000
2011 12 1,367,000,000
2010 12 1,446,000,000
2009 12 1,450,000,000
2008 12 1,453,000,000

 












Bloomberg News for ASTRAZENECA:



Google News for ASTRAZENECA:

StreetInsider.com - 2 hours ago
AstraZeneca (AZN) Reports FASENRA (benralizumab) Shows ...
AstraZeneca (AZN) Reports FASENRA (benralizumab) Shows Consistent Safety and Sustained Efficacy in Long-Term Phase III BORA Trial in ...
Top Stocks News (press release) - 22 minutes ago
Latest alterations:: AstraZeneca PLC, (NYSE: AZN)
AstraZeneca PLC institutional ownership is held at 4.2% while insider ownership was 17%. As of now, AZN has a P/S, P/E and P/B values of ...
PressOracle
AstraZeneca (AZN) Gets EU Nod for New Formulation of Bydureon
The expanded indication will definitely boost sales of the drug in the future quarters and will help AstraZeneca drive its revenues. However ...
Global Export Lines (press release)
AstraZeneca: FASENRA Shows Consistent Safety, Efficacy In Phase ...
(RTTNews.com) - AstraZeneca plc (AZN.L, AZN) announced results from the Phase III extension BORA trial evaluating the long-term safety and ...
Wall Street Morning
A Look At AstraZeneca PLC's (LON:AZN) Exceptional Fundamentals
Attractive stocks have exceptional fundamentals. In the case of AstraZeneca PLC (LON:AZN), there's is a company with a a great track record of ...
Zacks.com - 30 Aug 2018
AstraZeneca: KRONOS Phase III Trial Met Eight Of Nine Primary ...
(RTTNews) - AstraZeneca Plc. (AZN.L, AZN) announced Monday that the KRONOS Phase III trial for PT010 triple combination therapy in ...
Nasdaq
Active Stock Evaluation – AstraZeneca (NYSE: AZN)
AstraZeneca (NYSE: AZN) has a good repute in the Healthcare sector. But the most critical factor is that the company is coping with paradoxical ...
Proactive Investors UK
Extremely Informative stocks: Noble Corporation plc, (NYSE: NE ...
AstraZeneca PLC, (NYSE: AZN) exhibits a change of -0.48% during last trading session, while the company closed its business at $37.45 with ...
Stock Market Wire
AstraZeneca Looks To Its Asthma Drug For Blockbuster Potential
Recently, AstraZeneca (NYSE:AZN) and its partner Amgen (NASDAQ:AMGN) announced that they had received breakthrough therapy ...
Nasdaq - 1 hour ago
The Outlook for AstraZeneca Is Positive, But It's Too Early to Pull the ...
AstraZeneca's (NYSE:AZN) profits look poised to resume growing, as a number of the drug company's new treatments are expected to be ...


Back